Press Releases from Axentis Pharma AG (2 total)
CYSTIC FIBROSIS - LIPOSOMAL TOBRAMYCIN RECEIVES SECOND ORPHAN DRUG DESIGNATION W …
PRE-CLINICAL DATA INDICATE UNIQUE MICROBIOLOGICAL PROFILE FOR ESTABLISHED ANTIBIOTIC
Zurich, 16 July 2009. An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a second orphan drug designation in the US only weeks after a first designation was granted. The recent designation relates to Burkholderia cepacia pathogens that can cause lethal infections in cystic fibrosis patients. For Axentis Pharma AG of Zurich, Switzerland, both designations…
CHRONIC LUNG DISEASE - AXENTIS PHARMA ATTRACTS INVESTMENT INTEREST
Zurich, 2. February 2009. Axentis Pharma AG is to present its recent successes in developing and financing a new therapeutic formulation for treating chronic lung disease at the 2nd Annual European Life Science CEO Forum in Zurich, Switzerland. This invited talk comes just three weeks after the company was asked to present its recent achievements at the Biotech Showcase 2009 in San Francisco, USA. Part of the company's ongoing success…
